|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Research Network;
Kandoth C, Schultz N, Cherniack AD, AκBani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McAlpine JN, Temkin SM and Mackay HJ:
Endometrial cancer: Not your grandmother's cancer. Cancer.
122:2787–2798. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weigelt B and Banerjee S: Molecular
targets and targeted therapeutics in endometrial cancer. Curr Opin
Oncol. 24:554–563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Janzen DM, Rosales MA, Paik DY, Lee DS,
Smith DA, Witte ON, Iruela-Arispe ML and Memarzadeh S: Progesterone
receptor signaling in the microenvironment of endometrial cancer
influences its response to hormonal therapy. Cancer Res.
73:4697–4710. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim JJ and Chapman-Davis E: Role of
progesterone in endometrial cancer. Semin Reprod Med. 28:81–90.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Banno K, Kisu I, Yanokura M, Tsuji K,
Masuda K, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Susumu N and
Aoki D: Progestin therapy for endometrial cancer: The potential of
fourth-generation progestin (review). Int J Oncol. 40:1755–1762.
2012.PubMed/NCBI
|
|
8
|
Umene K, Banno K, Kisu I, Yanokura M,
Nogami Y, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, et
al: New candidate therapeutic agents for endometrial cancer:
Potential for clinical practice (review). Oncol Rep. 29:855–860.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morice P, Leary A, Creutzberg C,
Abu-Rustum N and Darai E: Endometrial cancer. Lancet.
387:1094–1108. 2016. View Article : Google Scholar
|
|
10
|
Duan Z, Gao B, Xu W and Xiong S:
Identification of TRIM22 as a RING finger E3 ubiquitin ligase.
Biochem Biophys Res Commun. 374:502–506. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu L, Zhou XM, Yang FF, Miao Y, Yin Y, Hu
XJ, Hou G, Wang QY and Kang J: TRIM22 confers poor prognosis and
promotes epithelial-mesenchymal transition through regulation of
AKT/GSK3β/β-catenin signaling in non-small cell lung cancer.
Oncotarget. 8:62069–62080. 2017.PubMed/NCBI
|
|
12
|
Sun Y, Ho GH, Koong HN, Sivaramakrishnan
G, Ang WT, Koh QM and Lin VC: Down-regulation of tripartite-motif
containing 22 expression in breast cancer is associated with a lack
of p53-mediated induction. Biochem Biophys Res Commun. 441:600–606.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wittmann S, Wunder C, Zirn B, Furtwangler
R, Wegert J, Graf N and Gessler M: New prognostic markers revealed
by evaluation of genes correlated with clinical parameters in Wilms
tumors. Genes Chromosomes Cancer. 47:386–395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saito-Kanatani M, Urano T, Hiroi H,
Momoeda M, Ito M, Fujii T and Inoue S: Identification of TRIM22 as
a progesterone-responsive gene in Ishikawa endometrial cancer
cells. J Steroid Biochem Mol Biol. 154:217–225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pikarsky E, Porat RM, Stein I, Abramovitch
R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and
Ben-Neriah Y: NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature. 431:461–466. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zandi E, Rothwarf DM, Delhase M, Hayakawa
M and Karin M: The IkappaB kinase complex (IKK) contains two kinase
subunits, IKKalpha and IKκBeta, necessary for IkappaB
phosphorylation and NF-kappaB activation. Cell. 91:243–252. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fan Y, Mao R and Yang J: NF-κb and STAT3
signaling pathways collaboratively link inflammation to cancer.
Protein Cell. 4:176–185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jefferies C, Wynne C and Higgs R:
Antiviral TRIMs: Friend or foe in autoimmune and autoinflammatory
disease? Nat Rev Immunol. 11:617–625. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong J, Jiao Y, Mu W, Lu B, Wei M, Sun L,
Hu S, Cui B, Liu X, Chen Z and Zhao Y: FκBP51 decreases cell
proliferation and increases progestin sensitivity of human
endometrial adenocarcinomas by inhibiting Akt. Oncotarget.
8:80405–80415. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Q, Lee CH, Peters LA, Mastropaolo LA,
Thoeni C, Elkadri A, Schwerd T, Zhu J, Zhang B, Zhao Y, et al:
Variants in TRIM22 that affect NOD2 signaling are associated with
very-early-onset inflammatory bowel disease. Gastroenterology.
150:1196–1207. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hugot JP, Chamaillard M, Zouali H, Lesage
S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M,
et al: Association of NOD2 leucine-rich repeat variants with
susceptibility to Crohn's disease. Nature. 411:599–603. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bonen DK, Ogura Y, Nicolae DL, Inohara N,
Saab L, Tanabe T, Chen FF, Foster SJ, Duerr RH, Brant SR, et al:
Crohn's disease-associated NOD2 variants share a signaling defect
in response to lipopolysaccharide and peptidoglycan.
Gastroenterology. 124:140–146. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Strober W and Watanabe T: NOD2, an
intracellular innate immune sensor involved in host defense and
Crohn's disease. Mucosal Immunol. 4:484–495. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bist P, Cheong WS, Ng A, Dikshit N, Kim
BH, Pulloor NK, Khameneh HJ, Hedl M, Shenoy AR, Balamuralidhar V,
et al: E3 Ubiquitin ligase ZNRF4 negatively regulates NOD2
signalling and induces tolerance to MDP. Nat Commun. 8:158652017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pellegrini E, Desfosses A, Wallmann A,
Schulze WM, Rehbein K, Mas P, Signor L, Gaudon S, Zenkeviciute G,
Hons M, et al: RIP2 filament formation is required for NOD2
dependent NF-κb signalling. Nat Commun. 9:40432018. View Article : Google Scholar
|
|
28
|
Watanabe T, Kitani A, Murray PJ, Wakatsuki
Y, Fuss IJ and Strober W: Nucleotide binding oligomerization domain
2 deficiency leads to dysregulated TLR2 signaling and induction of
antigen-specific colitis. Immunity. 25:473–485. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park JH, Kim YG, McDonald C, Kanneganti
TD, Hasegawa M, Body-Malapel M, Inohara N and Nunez G: RICK/RIP2
mediates innate immune responses induced through Nod1 and Nod2 but
not TLRs. J Immunol. 178:2380–2386. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Udden SMN, Peng L, Gan JL, Shelton JM,
Malter JS, Hooper LV and Zaki MH: NOD2 suppresses colorectal
tumorigenesis via downregulation of the tlr pathways. Cell Rep.
19:2756–2770. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Turrini F, Saliu F, Forlani G, Das AT, Van
Lint C, Accolla RS, Berkhout B, Poli G and Vicenzi E:
Interferon-inducible TRIM22 contributes to maintenance of HIV-1
proviral latency in T cell lines. Virus Res. 269:1976312019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vicenzi E and Poli G: The
interferon-stimulated gene TRIM22: A double-edged sword in HIV-1
infection. Cytokine Growth Factor Rev. 40:40–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lim KH, Park ES, Kim DH, Cho KC, Kim KP,
Park YK, Ahn SH, Park SH, Kim KH, Kim CW, et al: Suppression of
interferon-mediated anti-HBV response by single CpG methylation in
the 5'-UTR of TRIM22. Gut. 67:166–178. 2018. View Article : Google Scholar
|
|
35
|
Yang C, Zhao X, Sun D, Yang L, Chong C,
Pan Y, Chi X, Gao Y, Wang M, Shi X, et al: Interferon alpha
(IFNa)-induced TRIM22 interrupts HCV replication by ubiquitinating
NS5A. Cell Mol Immunol. 13:94–102. 2016. View Article : Google Scholar
|
|
36
|
Zhan W, Han T, Zhang C, Xie C, Gan M, Deng
K, Fu M and Wang JB: TRIM59 promotes the proliferation and
migration of non-small cell lung cancer cells by upregulating cell
cycle related proteins. PLoS One. 10:e01425962015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Clemente JC, Ursell LK, Parfrey LW and
Knight R: The impact of the gut microbiota on human health: An
integrative view. Cell. 148:1258–1270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kawai T and Akira S: Regulation of innate
immune signalling pathways by the tripartite motif (TRIM) family
proteins. EMBO Mol Med. 3:513–527. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu WS, Xu ZX, Hindman WN, Salomoni P,
Pandolfi PP and Chang KS: Promyelocytic leukemia protein sensitizes
tumor necrosis factor alpha-induced apoptosis by inhibiting the
NF-kappaB survival pathway. J Biol Chem. 278:12294–12304. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gack MU, Shin YC, Joo CH, Urano T, Liang
C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S and Jung JU: TRIM25
RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated
antiviral activity. Nature. 446:916–920. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang K, Shi HX, Liu XY, Shan YF, Wei B,
Chen S and Wang C: TRIM21 is essential to sustain IFN regulatory
factor 3 activation during antiviral response. J Immunol.
182:3782–3792. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kong HJ, Anderson DE, Lee CH, Jang MK,
Tamura T, Tailor P, Cho HK, Cheong J, Xiong H, Morse HC III and
Ozato K: Cutting edge: Autoantigen Ro52 is an interferon inducible
E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression
in macrophages. J Immunol. 179:26–30. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xu M and Zhang Y: Morin inhibits ovarian
cancer growth through inhibition of NF-κB signaling pathway.
Anticancer Agents Med Chem. 19:2243–2250. 2019. View Article : Google Scholar
|
|
44
|
Lim WK, Chai X, Ghosh S, Ray D, Wang M,
Rasheed SAK and Casey PJ: Ga-13 induces CXC motif chemokine ligand
5 expression in prostate cancer cells by transactivating NF-κB. J
Biol Chem. 294:18192–18206. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tilborghs S, Corthouts J, Verhoeven Y,
Arias D, Rolfo C, Trinh XB and van Dam PA: The role of nuclear
factor-kappa B signaling in human cervical cancer. Crit Rev Oncol
Hematol. 120:141–150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qin X, Yan M, Wang X, Xu Q, Wang X, Zhu X,
Shi J, Li Z, Zhang J and Chen W: Cancer-associated
fibroblast-derived IL-6 promotes head and neck cancer progression
via the osteopontin-NF-kappa B signaling pathway. Theranostics.
8:921–940. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Qiu H, Huang F, Xiao H, Sun B and Yang R:
TRIM22 inhibits the TRAF6-stimulated NF-κB pathway by targeting
TAB2 for degradation. Virol Sin. 28:209–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li Q and Verma IM: NF-kappaB regulation in
the immune system. Nat Rev Immunol. 2:725–734. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yu S, Gao B, Duan Z, Xu W and Xiong S:
Identification of tripartite motif-containing 22 (TRIM22) as a
novel NF-κB activator. Biochem Biophys Res Commun. 410:247–251.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen GY, Liu M, Wang F, Bertin J and Nunez
G: A functional role for Nlrp6 in intestinal inflammation and
tumorigenesis. J Immunol. 186:7187–7194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Girardin SE, Boneca IG, Viala J,
Chamaillard M, Labigne A, Thomas G, Philpott DJ and Sansonetti PJ:
Nod2 is a general sensor of peptidoglycan through muramyl dipeptide
(MDP) detection. J Biol Chem. 278:8869–8872. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Watanabe T, Asano N, Meng G, Yamashita K,
Arai Y, Sakurai T, Kudo M, Fuss IJ, Kitani A, Shimosegawa T, et al:
NOD2 down-regulates colonic inflammation by IRF4-mediated
inhibition of K63-linked polyubiquitination of RICK and TRAF6.
Mucosal Immunol. 7:1312–1325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Watanabe T, Asano N, Murray PJ, Ozato K,
Tailor P, Fuss IJ, Kitani A and Strober W: Muramyl dipeptide
activation of nucleotide-binding oligomerization domain 2 protects
mice from experimental colitis. J Clin Invest. 118:545–559.
2008.PubMed/NCBI
|
|
54
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
